Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
|
|
- Shanon Holt
- 5 years ago
- Views:
Transcription
1 Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott R, Morse MA, Wong KYM, Neyns B, Leach JL, Garcia-Alfono P, Lee JJ, Hill A, Lenz H-J, Desai J, Moss RA, Cao ZA, Ledeine J-M, Tang H, Kopetz S, Andre T
2 Introduction Globally, colorectal cancer (CRC) is the fourth leading cause of cancerrelated death 1 Approximately 4% of patients with metastatic CRC have a high degree of microsatellite instability (MSI-H) due to a deficiency in the DNA mismatch repair system (dmmr) 2,3 These patients may be less responsive to conventional chemotherapy than patients who are MMR proficient 3 dmmr/msi-h CRC is associated with elevated levels of tumor neoantigens and tumor-infiltrating lymphocytes and upregulated expression of checkpoint regulators in immune cells, including PD-1 and PD-L1 4,5 CheckMate 142 is a phase II study investigating the efficacy and safety of nivolumab ± ipilimumab in patients with metastatic dmmr/msi-h CRC 1. International Agency for Research on Cancer. GLOBOCAN Accessed January 24, Goldstein J, et al. Ann Oncol. 214;25(5): Venderbosch S, et al. Clin Cancer Res. 214;2(2): Giannakis M, et al. Cell Reports. 216;15(4): Llosa NJ, et al. Cancer Discov. 215;5(1): Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
3 Study Design Stage 1 a Stage 2 b Patients Histologically confirmed metastatic/recurrent CRC dmmr/msi-h per local laboratory 1 prior line of therapy Nivolumab 3 mg/kg q2w Nivolumab 3 mg/kg q2w Stage 1 c Nivolumab 3 mg/kg + ipilimumab 1 mg/kg q3w for 4 doses Then nivolumab 3 mg/kg q2w 74 patients were treated in monotherapy stages 1 and 2 (DBL Sept 216) Stage 2 d Nivolumab 3 mg/kg + ipilimumab 1 mg/kg q3w for 4 doses then nivolumab 3 mg/kg q2w Primary endpoint: ORR per investigator assessment Secondary endpoint: ORR per blinded independent central review (BICR) Other endpoints: PFS, OS, biomarkers, safety, and tolerability q2w, every 2 weeks; q3w, every 3 weeks a Enrollment complete; b Opened based on an adequate ORR (CR + PR) in patients with centrally confirmed MSI-H CRC treated in mstage 1; c Opened despite an adequate ORR in mstage 1 to proceed to mstage2; d Opened based on an adequate ORR in cstage 1 Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
4 Response assessment by blinded independent central review (BICR) and investigator Tumor assessments were performed using CT or MRI per RECIST v1.1 Evaluated: at baseline; q6w 24 weeks; q12w until disease progression or discontinuation Biomarker assessments: Methods PD-L1 expression was assessed using the Dako 28-8 pharmdx assay Evaluated: tumor cell PD-L1 expression ( 1% or <1%); abundance of tumor-associated immune cells expressing PD-L1 (rare, intermediate, or numerous) BRAF and KRAS mutation status was determined by investigators per local guidelines Characterization of Lynch syndrome was determined by investigators based on clinical records Patient-reported outcomes were evaluated by the EORTC QLQ-C3 and the EQ-5D EORTC, European Organisation for Research and Treatment of Cancer; q6w, every 6 weeks; q12w, every 12 weeks; RECIST, Response Evaluation Criteria In Solid Tumors Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
5 Patients, n (%) Baseline Characteristics dmmr/msi-h per Local Laboratory [n = 74] Median age (range), years 52.5 (26 79) Male, n (%) 44 (59.5) Race, n (%) White Black Other ECOG performance status, n (%) a 1 Disease stage at diagnosis I III IV Prior lines of therapy b (87.8) 7 (9.5) 2 (2.7) 32 (43.2) 42 (56.8) 41 (55.4) 33 (44.6) 1 (1.4) 11 (14.9) 22 (29.7) 4 (54.1) Prior radiotherapy 27 (36.5) Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
6 Baseline Characteristics Patients, n (%) Clinical history of Lynch syndrome, n (%) Yes No Unknown Mutation status BRAF/KRAS wildtype BRAF mutated KRAS mutated Tumor PD-L1 expression quantifiable at baseline a 1% <1% Abundance of PD-L1 expressing tumor-associated immune cells a Rare Intermediate Numerous dmmr/msi-h per Local Laboratory [n = 74] 23 (31.1) 26 (35.1) 25 (33.8) 28 (37.8) 12 (16.2) 26 (35.1) n = (28.4) 45 (6.8) n = (34.8) 2 (3.3) 23 (34.8) a PD-L1 status was not evaluable in 8 patients. Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
7 Exposure and Disposition Patients, n (%) dmmr/msi-h per Local Laboratory [n = 74] Median follow-up (range), months 7.4 ( ) Median number of doses (range) 13 (1 54) Continuing treatment 4 (54.1) Discontinued treatment 34 (45.9) Reasons for discontinuing treatment Disease progression Treatment-related toxicity Maximum clinical benefit Patient decision Withdrawn consent 27 (36.5) 4 (5.4) 1 (1.4) 1 (1.4) 1 (1.4) Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
8 Response and Disease Control dmmr/msi-h per Local Laboratory [n = 74] dmmr/msi-h per Central Laboratory [n = 53] Patients, n (%) ORR, n (%) 95% CI Investigator BICR Investigator BICR 23 (31.1) 2.8, (27.) 17.4, (35.8) 23.1, (32.1) 19.9, 46.3 Best overall response, n (%) CR PR SD PD Unable to determine 23 (31.1) 29 (39.2) 18 (24.3) 4 (5.4) 2 (2.7) 18 (24.3) 28 (37.8) 2 (27.) 6 (11.1) 19 (35.8) 21 (39.6) 1 (18.9) 3 (5.7) 1 (1.9) 16 (3.2) 21 (39.6) 12 (22.6) 3 (5.7) Disease control for 12 weeks, n (%) a 51 (68.9) 46 (62.2) 39 (73.6) 37 (69.8) BICR, blinded independent central review a Patients with CR, PR, or SD for 12 weeks Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
9 Change in Tumor Burden a On treatment Off treatment CR or PR First occurrence of new lesion Change truncated to 1% a Patients evaluated as dmmr/msi-h by local laboratory. Tumor evaluations by investigator assessment. Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
10 Characterization of Response and Stable Disease Patients With Response (n = 23) a Investigator Assessed Median TTR: 2.8 months Median DOR: not reached 83% (19/23) responses ongoing Patients With Stable Disease (n = 29) a Censored Last dose when patient off treatment First response Death Weeks Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
11 Progression-Free Survival Probability of PFS, % a PFS per Investigator Median [95% CI], months 9.6 [4.3, NE] 12-month rate [95% CI], % 48.4 [33.6, 61.7] PFS per BICR 12-month rate [95% CI], % 45.6 [32.2, 58.1] No. at risk Months BICR, blinded independent central review; NE, not estimable a Investigator assessed dmmr/msi-h by local laboratory Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
12 Overall Survival Probability of Survival, % a No. at risk Median OS [95% CI], months 12-month OS rate [95% CI], % Months NR [17.1, NE] 73.8 [59.8, 83.5] NR, not reached a dmmr/msi-h assessed by local laboratory Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
13 Reduction in Target Lesions Regardless of PD-L1 Expression Investigator-Assessed Best Change in Target Lesion Size, % Tumor PD-L1 Expression 1% <1% + Confirmed CR/PR Investigator-Assessed Best Change in Target Lesion Size, % Abundance of PD-L1 Expressing Tumor-Associated Immune Cells Rare Intermediate Numerous + Confirmed CR/PR ORR, n/n (%) Investigator BICR Tumor PD-L1 expression 1% < 1% 6/21 (28.6) 13/45 (28.9) 7/2 (35.) 11/45 (24.4) ORR, n/n (%) Investigator BICR Abundance of PD-L1 expressing immune cells Rare Intermediate Numerous 5/23 (21.7) 5/2 (25.) 9/23 (39.1) 4/22 (18.2) 4/2 (2.) 1/23 (43.5) Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
14 Reduction in Target Lesions Regardless of BRAF Mutation Status and Lynch Syndrome Investigator-Assessed Best Change in Target Lesion Size, % BRAF Mutation Status Mutant Wildtype + Confirmed CR/PR Investigator-Assessed Best Change in Target Lesion Size, % Clinical History of Lynch Syndrome Yes No + Confirmed CR/PR ORR, n/n (%) Investigator BICR BRAF mutation status Mutant Wild type 3/12 (25.) 12/28 (42.9) 2/12 (16.7) 9/27 (33.3) KRAS mutation status Mutant Wild type 7/26 (26.9) 12/28 (42.9) 6/26 (23.1) 9/27 (33.3) ORR, n/n (%) Investigator BICR Clinical history of Lynch syndrome Yes No 8/23 (34.8) 8/26 (3.8) 8/23 (34.8) 6/26 (23.1) Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
15 Safety Five patients b (6.8%) experienced 1 AE leading to discontinuation, including abdominal pain, increased ALT, colitis, acute kidney injury, stomatitis, and vomiting (1 of each event) No deaths were reported due to study drug toxicity All Patients [n = 74] Patients, n (%) Any grade Grade 3 4 Any TRAE 51 (68.9) a 15 (2.3) TRAEs reported in 1% of patients Fatigue Diarrhea Pruritus Lipase increased Rash 17 (23.) 16 (21.6) 1 (13.5) 9 (12.2) 8 (1.8) 1 (1.4) 1 (1.4) 6 (8.1) a One grade 5 event of sudden death was reported; this death was not attributed to study drug toxicity on autopsy b One of these patients discontinued due to disease progression Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
16 Patient-Reported Outcomes: EORTC QLQ-C3 Mean Change From Baseline Better Worse Global Health Status/ QOL Mean Change From Baseline Better Worse Role Functioning Clinically meaningful ( 1-point change) 1 improvements were reported in QOL, functioning, and symptoms as early as week Weeks Weeks Mean Change From Baseline Worse Better 13 Fatigue Weeks Patients Mean Change From Baseline Worse Better 13 Appetite Loss Weeks Patients Mean Change From Baseline Better Worse 13 Pain Weeks Patients QOL, quality of life 1. Osoba D, et al. J Clin Oncol. 1998;16(1): Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
17 Patient-Reported Outcomes: EQ-5D Population Norm Patients Patients who continued treatment for 19 weeks achieved a level of health per the EQ-5D VAS that would be regarded as equal to or exceeding the general health of many populations 1 VAS, Visual Analog Scale 1. Janssen B, et al. In: Szende A, et al (Eds). Self-Reported Population Health: An International Perspective based on EQ-5D. Springer Netherlands, 214:19-3. Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
18 Conclusions Nivolumab monotherapy provided durable responses, disease control, and long-term survival (12-month OS rate, 73.8%) in patients with dmmr/msi-h metastatic CRC Responses were observed regardless of tumor or immune cell PD-L1 expression, BRAF or KRAS mutation status, or clinical history of Lynch syndrome Nivolumab was well tolerated, with a safety profile consistent with that reported in other solid tumors; no new safety signals were observed Patient-reported outcome analyses showed clinically meaningful improvements in functioning, symptoms, and quality of life These results suggest that nivolumab should be considered a new standard of care for patients with previously treated dmmr/msi-h advanced CRC Overman MJ, et al. J Clin Oncol. 217;35(Suppl 4): Abstract 519.
Bristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCarcinoma colorettale: personalizzazione del trattamento
33 Incontro Oncologico del Triveneto Padova, Aprile 2017 Carcinoma colorettale: personalizzazione del trattamento Fotios Loupakis, MD PhD U.O.C. Oncologia Medica 1 Dipartimento di Oncologia Clinica e Sperimentale
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmunoterapia en Cáncer colorrectal. Manuel Benavides
Immunoterapia en Cáncer colorrectal Manuel Benavides Agenda - Cáncer colorrectal / MSI - MSI-H / MSI-L o MSI-S - Inhibidores de Checkpoints Molecular Pathways in Colorectal Cancer tability or MSI (15%)
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Overman MJ, McDermott R, Leach JL, et al. Nivolumab
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationINMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO. Dra. Lara Iglesias H.U.12 Octubre
INMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO Dra. Lara Iglesias H.U.12 Octubre INTRODUCCIÓN INFORME SEOM DE EVALUACIÓN DE FÁRMACOS: NIVOLUMAB EN CÁNCER EPIDERMOIDE DE CABEZA Y CUELLO
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationImmunotherapy in GI cancers
Immunotherapy in GI cancers Julien TAIEB Sorbonne Paris Cité Hopital Européen Georges Pompidou Inserm U97 J Taieb ESDO Leuven 217 How to progress in GI cancer treatment Better define subgroups With different
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationColorectal Cancer: Novel Insights
Colorectal Cancer: Novel Insights Richard Kim M.D. Associate Professor Service Chief of Medical Oncology Department of Gastrointestinal Oncology Moffitt Cancer Center Tampa, FL Richard Kim, MD Colorectal
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy for Upper GI Cancers
Immunotherapy for Upper GI Cancers Esophageal Adenocarcinoma GE Junction Adeno Gastric Carcinoma Ahmed Zakari MD Medical Director of GI Cancer Program, Florida Hospital Cancer Institute Associate Professor
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationGI SLIDE DECK 2017 Selected abstracts from:
GI SLIDE DECK 217 Selected abstracts from: 217 Gastrointestinal Cancers Symposium 19 21 January 217 San Francisco, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationpcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial M inistries of Health (with the exception
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationCost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.
Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationEric Van Cutsem University Hospitals Leuven, Belgium
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti Epidermal Growth Factor Receptor Antibody Cetuximab for BRAF V600E Metastatic Colorectal
More informationSpecial situations: Patients with liver metastasis or liver primary tumor. Erika Martinelli, MD PhD Medical Oncologist
Special situations: Patients with liver metastasis or liver primary tumor Erika Martinelli, MD PhD Medical Oncologist Outline: Liver (anatomy, basic functions) Liver Immuno-landscape Immuno-landscape in
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationASCO 2016 * Investor Meeting June 4, *American Society of Clinical Oncology, June 3-7, 2016 ASCO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ASCO 2016 * Investor Meeting June 4, 2016 *American Society of Clinical Oncology, June 3-7, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future plans
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationI tumori gastrointestinali
I tumori gastrointestinali Carmine Pinto Clinical Cancer Centre Oncologia Medica IRCCS-Arcispedale S.Maria Nuova Reggio Emilia Agenda Mutation burden and Immunogenicità Immunonoterapia nel carcinoma gastrico
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationPresentation by Dr. Thomas Yau on behalf of his co-authors
4078 First presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, Illinois, USA, June 3-7, 2016. Reused with permission from the American Society of Clinical Oncology
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationAttached from the following page is the press release made by BMS for your information.
June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More information